Many of us begin a new year hoping to become better versions of ourselves. Some aim to improve their health, others focus on ...
Eisai and Biogen have completed their rolling biologics license application in the US for a subcutaneous formulation of Alzheimer's disease therapy Leqembi previously delayed by the FDA on procedural ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback